Search results
Jun 26, 2024 · Illumina is a global leader in genomic technologies, offering products and services for research and clinical applications. Learn about its innovative platforms, microarrays, software, and impact in action.
- Careers
By nurturing an inclusive and caring environment, we magnify...
- Explore All Products
Explore All Products - Illumina | Sequencing and array...
- See All Learning Options
See All Learning Options - Illumina | Sequencing and array...
- View All Support
View All Support - Illumina | Sequencing and array solutions...
- Contact Us
Contact Us - Illumina | Sequencing and array solutions to...
- Sequencing
Illumina sequencing enables a wide variety of applications,...
- Stock Information
At Illumina, Inc., we promise to treat your data with...
- Financial Information
At Illumina, Inc., we promise to treat your data with...
- Careers
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers.
Find the latest Illumina, Inc. (ILMN) stock quote, history, news and other vital information to help you with your stock trading and investing.
Delivering Value to Investors. A global leader in DNA sequencing and array-based technologies, Illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments.
May 26, 2022 · SINGAPORE, 26 May 2022 – Precision Health Research, Singapore (PRECISE), the central entity implementing Singapore’s National Precision Medicine (NPM) strategy, and Illumina, Inc (Illumina), a leader in genomics technology, announced today a strategic partnership to sequence and analyse 100,000 Singaporean whole genomes (SG100K), to create ...